Braeburn Pharmaceuticals   Report issue

For profit Phase 1 Phase 3
Founded: Plymouth Meeting PA United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2012
NCT00447564
First Marketed Drug
2018
buprenorphine
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

BRAEBURN | BRAEBURN PHARMA INC

Active Ingredients

Marketed Drugs (1)

buprenorphine (2018)

Drugs in Phase 3 Trials (2)

buprenorphine (11 trials)

risperidone (risperdal) (2 trials)

Drugs in Phase 1 Trials (2)

ati-9242 (1 trial)

fallypride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Behavior, Addictive (Phase 3)

Chronic Pain (Phase 3)

Low Back Pain (Phase 3)

Mood Disorders (Phase 2)

Opioid-Related Disorders (Phase 3)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 3)

Substance-Related Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 4